Specialist Updates 
Oncology

Addition of immune therapy ‘shows promise’ in gastric cancer

But two trials of first-line therapy have differing overall survival outcomes
Medicom Staff writer
0
25 September 2020
Save
Please login to bookmark Close

AusDoc brings you the latest news from the European Society for Medical Oncology virtual congress 2020.

Two trials of nivolumab plus chemotherapy versus chemotherapy show improvements in progression-free survival (PFS) for patients with advanced gastric cancer, but they have differing findings for overall survival (OS).

Both trials (CheckMate-649 and ATTRACTION-4) were reported to delegates at the European Society for Medical Oncology (ESMO) virtual congress 2020.

Reporting on a prespecified analysis of the phase 3 CheckMate-649 trial, results were given for more than 1500 patients randomised to two arms of the (three-armed) trial: nivolumab (360mg Q3W or 240mg Q2W) + chemotherapy (XELOX Q3W or FOLFOX Q2W), or chemotherapy.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .